Company Description
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies.
The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.
It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma.
Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
| Country | United States |
| IPO Date | Jun 18, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 152 |
| CEO | Brent Pfeiffenberger M.B.A., Pharm.D. |
Contact Details
Address: 3675 Market Street Philadelphia, Pennsylvania United States | |
| Website | https://www.centurytx.com |
Stock Details
| Ticker Symbol | IPSC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001850119 |
| CUSIP Number | 15673T100 |
| ISIN Number | US15673T1007 |
| Employer ID | 84-2040295 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Brent Pfeiffenberger M.B.A., Pharm.D. | Chief Executive Officer & Director |
| Dr. Morgan Conn Ph.D. | Chief Financial Officer |
| Dr. Shane Williams Ph.D. | Chief People Officer |
| Dr. Adrienne Farid Ph.D. | Chief Development Officer, CCO & Head of Early Development |
| Dr. Chad A. Cowan Ph.D. | Chief Scientific Officer |
| Dr. Gregory Russotti Ph.D. | Chief Technology & Manufacturing Officer |
| Dr. Nick Trede M.D., Ph.D. | Senior Vice President & Head of Clinical Development |
| Katja Buhrer | SVice President, Head of Corporate Affairs & Strategy |
| Kenneth J. Dow J.D. | Senior Vice President of General Counsel |
| Michael Naso Ph.D. | Senior Vice President of Cell Engineering |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 13, 2025 | 8-K | Current Report |
| Dec 13, 2024 | 8-K | Current Report |
| Dec 06, 2024 | 4 | Filing |
| Nov 27, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 05, 2024 | 4 | Filing |
| Nov 05, 2024 | 4 | Filing |
| Nov 05, 2024 | 8-K | Current Report |